Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2015 Jul 26;288(1):95–105. doi: 10.1016/j.taap.2015.07.017

Table 3.

Interaction between SNPs and well arsenic over the course of follow-up in relation to diastolic blood pressure.

Gene db SNP ID MAF
(%)
Genetic
modela
Arsenic*Timeb
(95% CI)
SNP*Timec
(95% CI)
Arsenic*SNP*Timed
(95% CI)
p-valuee q-valuef
APOE rs429358 9.6 Dominant 0.08 (−0.02, 0.18) −0.02 (−0.37, 0.33) 0.06 (−0.15, 0.27) 0.56 0.99
Recessive 0.08 (−0.01, 0.18) 0.77 (−0.72, 2.25) 0.95 (0.03, 1.88) 0.04 0.82

AS3MT rs9527 7.1 Dominant 0.14 (0.04, 0.24) 0.13 (−0.26, 0.52) 0.22 (0.02, 0.42) 0.03 0.74
Recessive 0.10 (0.01, 0.19) 1.22 (−0.71, 3.14) −1.30 (−2.65, 0.04) 0.06 0.88
rs4290163 8.1 Dominant 0.13 (0.03, 0.23) −0.20 (−0.59, 0.18) 0.26 (0.03, 0.49) 0.03 0.74
Recessive 0.10 (0.01, 0.19) 1.36 (−0.16, 2.87) −0.60 (−1.63, 0.42) 0.25 0.88

GSTM1 rs4147567 4.0 Dominant 0.07 (−0.03, 0.16) −0.47 (−0.99, 0.05) 0.36 (0.09, 0.63) 0.01 0.74

GSTP1 rs6591256 32.7 Dominant 0.01 (−0.10, 0.12) −0.16 (−0.43, 0.11) 0.24 (0.08, 0.40) 0.003 0.70
Recessive 0.08 (−0.01, 0.18) −0.13 (−0.58, 0.32) 0.20 (−0.06, 0.46) 0.14 0.88
rs1695 44.0 Dominant 0.36 (0.10, 0.61) −0.04 (−0.47, 0.40) 0.30 (0.04, 0.57) 0.02 0.74

HMOX1 rs5755718 17.1 Dominant 0.03 (−0.08, 0.15) −0.04 (−0.40, 0.31) 0.26 (0.04, 0.48) 0.02 0.74
Recessive 0.07 (−0.05, 0.18) −0.20 (−0.67, 0.26) 0.16 (−0.11, 0.43) 0.24 0.88
rs8139532 8.5 Dominant 0.05 (−0.05, 0.15) −0.13 (−0.49, 0.24) 0.29 (0.07, 0.52) 0.01 0.74
rs16995662 8.2 Dominant 0.06 (−0.04, 0.16) −0.09 (−0.46, 0.28) 0.25 (0.03, 0.48) 0.03 0.74
rs2269534 8.1 Dominant 0.06 (−0.04, 0.16) −0.12 (−0.50, 0.25) 0.25 (0.03, 0.48) 0.03 0.74

IL6 rs2069840 14.3 Dominant 0.12 (0.02, 0.23) 0.21 (−0.09, 0.51) −0.11 (−0.29, 0.07) 0.24 0.88
Recessive −0.48 (−0.99, 0.03) −1.08 (−2.07, −0.10) 0.59 (0.07, 1.10) 0.02 0.74
rs13306435 10.9 Dominant 0.16 (0.05, 0.26) 0.27 (−0.06, 0.60) 0.19 (0.01, 0.36) 0.04 0.82
Recessive 0.12 (0.02, 0.21) 0.03 (−1.12, 1.18) −0.37 (−1.12, 0.37) 0.33 0.92
rs1554606 7.8 Dominant 0.13 (0.03, 0.23) −0.22 (−0.61, 0.17) 0.28 (0.04, 0.52) 0.02 0.74
Recessive 0.10 (0.00, 0.19) 1.36 (−0.16, 2.87) −0.60 (−1.63, 0.42) 0.25 0.88
rs1474347 20.8 Dominant 0.20 (0.08, 0.31) −0.26 (−0.54, 0.01) 0.19 (0.03, 0.34) 0.02 0.74
Recessive 0.12 (0.02, 0.21) 0.13 (−0.47, 0.74) 0.02 (−0.46, 0.49) 0.94 0.99

NOS3 rs3918198 8.2 Dominant 0.06 (−0.04, 0.16) −0.09 (−0.46, 0.28) 0.25 (0.02, 0.47) 0.03 0.74
rs1799983 8.8 Dominant 0.05 (−0.05, 0.15) −0.12 (−0.48, 0.24) 0.30 (0.07, 0.52) 0.01 0.74

PNP rs17882836 49.2 Dominant 0.05 (−0.10, 0.21) −0.14 (−0.45, 0.18) 0.04 (−0.13, 0.21) 0.65 0.99
Recessive −0.08 (−0.26, 0.10) −0.27 (−0.59, 0.05) 0.21 (0.02, 0.40) 0.03 0.74

TNF rs4248159 5.6 Dominant 0.14 (0.04, 0.24) −0.37 (−0.80, 0.05) 0.21 (0.02, 0.40) 0.03 0.74

Abbreviations: SNPs, single nucleotide polymorphisms; CI, confidence interval; DBP, diastolic blood pressure.

a

Recessive models are not shown for variants where fewer than 10 individuals possessed the homozygous recessive genotype

b

Coefficient in relation to interaction between well arsenic level and time

c

Coefficient in relation to interaction between each SNP in the dominant or recessive genetic models and time.

d

Coefficient in relation to the three-way interaction between each SNP, time and well arsenic in the dominant, or recessive genetic models.

e

P values for interaction adjusted for sex, age at enrollment, body mass index, smoking status (never, past, and current), educational attainment and diabetes at baseline, prior to FDR correction for multiple comparisons.

f

Q values are adjusted P values for interaction adjusted for sex, age at enrollment, body mass index, smoking status (never, past, and current), educational attainment and diabetes at baseline, after FDR correction for multiple comparisons.